GalChimia is a member of the consortium Humanfarma, whose goal is the development of new active compounds for drug discovery through translational research directly in patient samples. The project, which has a budget of €4.1 M and has been partially financed by the Ministry of Economy and Competitiveness under the INNPACTO subprogramme, also involves the participation of the University of Santiago de Compostela (USC), the Barcelona Science Park (PCB), and three biotech companies: Oryzon Genomics, Vivia Allosterics and Vivia Biotech, which is the coordinator of the project.
Comunication and Dissemination
- Article Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for “Diabesity”, published in J. Med. Chem. 2022, 65(7), 5449–5461. DOI: 10.1021/acs.jmedchem.1c01842 (Open Access)
GalChimia thanks all the partners in the Humanfarma project for their involvement and teamwork, which have been key to the success of the project.
